

Table S1. Antthrombotic agents, ATC codes**B01AA Vitamin K antagonists**

| ATC code | Name |
|----------|----------------------|
| B01AA01 | dicoumarol |
| B01AA02 | phenindione |
| B01AA03 | warfarin |
| B01AA04 | phenprocoumon |
| B01AA07 | acenocoumarol |
| B01AA08 | ethyl biscoumacetate |
| B01AA09 | clorindione |
| B01AA10 | diphenadione |
| B01AA11 | tiocloamarol |
| B01AA12 | fluindione |

B01AB Heparin group

| ATC code | Name |
|----------|-----------------------|
| B01AB01 | heparin |
| B01AB02 | antithrombin III |
| B01AB04 | dalteparin |
| B01AB05 | enoxaparin |
| B01AB06 | nadroparin |
| B01AB07 | parnaparin |
| B01AB08 | reviparin |
| B01AB09 | danaparoid |
| B01AB10 | tinzaparin |
| B01AB11 | sulodexide |
| B01AB12 | bemiparin |
| B01AB51 | heparin, combinations |

B01AC Platelet aggregation inhibitors excl. heparin

| ATC code | Name |
|----------|----------------------|
| B01AC01 | ditazole |
| B01AC02 | cloricromen |
| B01AC03 | picotamide |
| B01AC04 | clopidogrel |
| B01AC05 | ticlopidine |
| B01AC06 | acetylsalicylic acid |
| B01AC07 | dipyridamole |
| B01AC08 | carbasalate calcium |
| B01AC09 | epoprostenol |
| B01AC10 | indobufen |
| B01AC11 | iloprost |
| B01AC13 | abciximab |
| B01AC15 | aloxiprin |
| B01AC16 | eptifibatide |
| B01AC17 | tirofiban |

TABLE S2. Population characteristics based on their antithrombotic use patterns.

| Characteristics | Users* | | p value |
|-----------------------------|--------------------------|----------------------|---------|
| | n=79,234 (9%) | | |
| | Primary care n=37,183 | Hospital n=42,051 | |
| Gender | | | |
| Female | 19 544 (52.6%) | 18 713 (45.5%) | < 0.001 |
| Male | 17 639 (47.4%) | 23 338 (55.5%) | |
| Age (y) | | | |
| Median, years (IQR) | 70 (57-82) | 70 (56-83) | |
| 18-25 | 418 (1.1%) | 412 (0.9%) | |
| 25-40 | 3 060 (8.3%) | 2 580 (6.1%) | |
| 40-55 | 4 758 (12.8%) | 6 716 (16%) | < 0.001 |
| 55-70 | 10 128 (27.2%) | 10 874 (25.9%) | |
| >70 | 18 819 (50.6%) | 21 469 (51.1%) | |
| Comorbidities | | | |
| Obesity | 7 743 (20.9%) | 8 928 (21.2%) | 0.160 |
| Cardiovascular diseases | 26 491 (72.5%) | 25 736 (61.2%) | < 0.001 |
| Hypertension | 21 169 (56.9%) | 22 141 (52.7%) | < 0.001 |
| Heart failure | 3 164 (8.5%) | 4 127 (9.8%) | < 0.001 |
| Arrhythmia | 8 758 (23.6%) | 7 131 (17%) | < 0.001 |
| Ischemic heart disease | 7 673 (20.6%) | 4 677 (11.1%) | < 0.001 |
| Coronary artery disease | 5 576 (15%) | 3 402 (8.1%) | < 0.001 |
| IAM | 3 576 (9.6%) | 1 779 (4.2%) | < 0.001 |
| Valvopathies | 1 340 (3.6%) | 1 184 (2.8%) | < 0.001 |
| Peripheral arterial disease | 1 638 (4.4%) | 1 370 (3.3%) | < 0.001 |
| Cancer history | 4 592 (12.3%) | 6 157 (14.6%) | < 0.001 |
| Hereditary thrombophilia | 111 (0.3%) | 40 (0.1%) | < 0.001 |
| Stroke | 5 615 (15.1%) | 3 805 (9%) | < 0.001 |
| Ischemic stroke | 5 471 (14.7%) | 3 603 (8.6%) | < 0.001 |
| Hemorrhagic stroke | 287 (0.8%) | 325 (0.8%) | 0.987 |
| Acute liver disease | 9 (0.02%) | 9 (0.02%) | 0.794 |

Table S3. Medications prescribed within six months before COVID-19 diagnosis

| Medicines | Non-users | | Primary care users. | | | Hospitals users | | |
|--|-----------------------------------|---------------------|------------------------------------|------------------------------------|----------------------------------|------------------------------------|------------------------------------|-----------------------------------|
| | All cases n=882,540 (100 %) | n=803,306 (91 %) | Global users n=37,183 (4,2%) | Prevalent users n=29,678 (%) | Incident users n=7,505 (%) | Global users n=42,051 (4,8%) | Prevalent users n=21,751 (%) | Incident users n=20,300 (%) |
| A10 Drugs used in diabetes | 60 308 (6.8%) | 42 107 (5.2%) | 9.040 (24.3%) | 8.594 (29.0%) | 446 (5.9%) | 9.161 (21.8%) | 6.703 (30.8%) | 2.458(12.1%) |
| A10A Insulins and analogues | 17 812 (2.0%) | 11 355 (1.4%) | 2.915 (7.8%) | 2.812 (9.5%) | 103 (1.4%) | 3.542 (8.4%) | 2.905 (13.4%) | 637 (3.1%) |
| A10B Blood glucose lowering drugs, excluding insulins | 53 414 (6.1%) | 37 245 (4.6%) | 8.205 (22.1%) | 7.806 (26.3%) | 399 (5.3%) | 7.964 (18.9%) | 5.723 (26.3%) | 2.241 (11.0%) |
| C01B Antiarrhythmics, class I and III | 4 281 (0.5%) | 2.419 (0.3%) | 1.049 (2.8%) | 1.040 (3.5%) | 9 (0.1%) | 813 (1.9%) | 763 (3.5%) | 50 (0.2%) |
| C02 Antihypertensives | 7 452 (0.8%) | 4.624 (0.6%) | 1.157 (3.1%) | 1.106 (3.7%) | 51 (0.7%) | 1.671 (4.0%) | 1.311 (6.0%) | 360 (1.8%) |
| C02C Antiadrenergic agents, peripherally acting | 6 930 (0.8%) | 4.247 (0.5%) | 1.084 (2.9%) | 1.039 (3.5%) | 45 (0.6%) | 1.599 (3.8%) | 1.256 (5.8%) | 343 (1.7%) |
| C03 Diuretics | 50 612 (57%) | 30.852 (3.8%) | 8.424 (22.7%) | 8.046 (27.1%) | 378 (5.0%) | 11.336(27.0%) | 9.206 (42.3%) | 2.130 (10.5%) |
| C03A Low-ceiling diuretics, thiazides | 5 605 (0.6%) | 3.846 (0.5%) | 649 (1.7%) | 603 (2.0%) | 46 (0.6%) | 1.110 (2.6%) | 807 (3.7%) | 303 (1.5%) |
| C03B Low-ceiling diuretics, excluding thiazides | 4 476 (0.5%) | 3.344 (0.4%) | 509 (1.4%) | 455 (1.5%) | 54 (0.7%) | 623 (1.5%) | 409 (1.9%) | 214 (1.1%) |
| C03C High-ceiling diuretics | 38 057 (4.3%) | 21.520 (2.7%) | 6.775 (18.2%) | 6.530 (22.0%) | 245 (3.3%) | 9.762 (23.2%) | 8.241 (37.9%) | 1.521 (7.5%) |
| C03D Aldosterone antagonists and other potassium-sparing agents | 7 656 (0.9%) | 4.290 (0.5%) | 1.573 (4.2%) | 1.546 (5.2%) | 27 (0.4%) | 1.793 (4.3%) | 1.624 (7.5%) | 169 (0.8%) |
| C03E Diuretics and potassium-sparing agents in combination | 2 559 (0.3%) | 1.871 (0.2%) | 319 (0.9%) | 282 (1.0%) | 37 (0.5%) | 369 (0.9%) | 233 (1.1%) | 136 (0.7%) |
| C07 Beta blocking agents | 48 225 (5.5%) | 30.167 (3.8%) | 10.318(27.7%) | 10.098(34.0%) | 220 (2.9%) | 7.740 (18.4%) | 6.670 (30.7%) | 1.070 (5.3%) |
| C07A Beta blocking agents | 46 821 (5.3%) | 29.072 (3.6%) | 10.130 (27.2%) | 9.923 (33.4%) | 207 (2.8%) | 7.619 (18.1%) | 6.597 (30.3%) | 1.022 (5.0%) |
| C07B Beta blocking agents and thiazides | 1 028 (0.1%) | 795 (0.1%) | 128 (0.3%) | 119 (0.4%) | 9 (0.1%) | 105 (0.2%) | 66 (0.3%) | 39 (0.2%) |
| C08 Calcium channel blockers | 30 323 (3.4%) | 19.734 (2.5%) | 4.758 (12.8%) | 4.548 (15.3%) | 210 (2.8%) | 5.831 (13.9%) | 4.469 (20.5%) | 1.362 (6.7%) |
| C08C Selective calcium channel blockers with mainly vascular effects | 26 856 (3.0%) | 17.714 (2.2%) | 3.947 (10.6%) | 3.745 (12.6%) | 202 (2.7%) | 5.195 (12.4%) | 3.899 (17.9%) | 1.296 (6.4%) |
| C08D Selective calcium channel blockers with direct cardiac effects | 3 717 (0.4%) | 2.130 (0.3%) | 866 (2.3%) | 857 (2.9%) | 9 (0.1%) | 721 (1.7%) | 654 (3.0%) | 67 (0.3%) |
| C09 Agents acting on the renin-angiotensin system | 126 782(14.4%) | 94.361 (11.7%) | 16.337 (43.9%) | 15.289 (51.5%) | 1.048(14.0%) | 16.084 (38.2%) | 10.918(50.2%) | 5.166 (25.4%) |

| | | | | | | | | |
|--|----------------|----------------|----------------|----------------|---------------|----------------|----------------|---------------|
| C09A ACE inhibitors, plain | 39 155 (4.4%) | 28.161 (3.5%) | 5.502 (14.8%) | 5.167 (17.4%) | 335 (4.5%) | 5.492 (13.1%) | 3.987 (18.3%) | 1.505 (7.4%) |
| C09B ACE inhibitors, combinations | 13 761 (1.6%) | 10.728 (1.3%) | 1.466 (3.9%) | 1.329 (4.5%) | 137 (1.8%) | 1.567 (3.7%) | 902 (4.1%) | 665 (3.3%) |
| C09C Angiotensin II receptor blockers (ARBs), plain | 39 587 (4.5%) | 28.894 (3.6%) | 4.864 (13.1%) | 4.565 (15.4%) | 299 (4.0%) | 5.829 (13.9%) | 4.095 (18.8%) | 1.734 (8.5%) |
| C09D Angiotensin II receptor blockers (ARBs), combinations | 42 218 (4.8%) | 31.549 (3.9%) | 5.456 (14.7%) | 5.122 (17.3%) | 334 (4.5%) | 5.213 (12.4%) | 3.465 (15.9%) | 1.748 (8.6%) |
| C10 Lipid modifying agents | 126 883(14.4%) | 94.811 (11.8%) | 17.696 (47.6%) | 16.763 (56.5%) | 933 (12.4%) | 14.376 (34.2%) | 10.200 (46.9%) | 4.176 (20.6%) |
| C10A Lipid modifying agents, plain | 114 481(13.0%) | 85.677 (10.7%) | 15.555 (41.8%) | 14.704 (49.5%) | 851 (11.3%) | 13.249 (31.5%) | 9.394 (43.2%) | 3.855 (19.0%) |
| C10AA HMG CoA reductase inhibitors | 103 737(11.8%) | 76.997 (9.6%) | 14.513 (39.0%) | 13.769 (46.4%) | 744 (9.9%) | 12.227 (29.1%) | 8.805 (40.5%) | 3.422 (16.9%) |
| C10B Lipid modifying agents, combinations | 15 103 (1.7%) | 10.879 (1.4%) | 2.648 (7.1%) | 2.557 (8.6%) | 91 (1.2%) | 1.576 (3.7%) | 1.189 (5.5%) | 387 (1.9%) |
| G03 Sex hormones and modulators of the genital system | 35 355 (4.0%) | 34.338 (4.3%) | 509 (1.4%) | 235 (0.8%) | 274 (3.7%) | 508 (1.2%) | 148 (0.7%) | 360 (1.8%) |
| G03A Hormonal contraceptives for systemic use | 28 919 (3.3%) | 28.450 (3.5%) | 208 (0.6%) | 45 (0.2%) | 163 (2.2%) | 261 (0.6%) | 44 (0.2%) | 217 (1.1%) |
| G03C Estrogens | 1 076 (0.1%) | 1.006 (0.1%) | 33 (0.1%) | 23 (0.1%) | 10 (0.1%) | 37 (0.1%) | 14 (0.1%) | 23 (0.1%) |
| H02 Corticosteroids for systemic use | 44 826 (5.1%) | 31.843 (4.0%) | 3.078 (8.3%) | 2.576 (8.7%) | 502 (6.7%) | 9.905 (23.6%) | 6.181 (28.4%) | 3.724 (18.3%) |
| H02A Corticosteroids for systemic use, plain | 44.826 (5.1%) | 31.843 (4.0%) | 3.078 (8.3%) | 2.576 (8.7%) | 502 (6.7%) | 9.905 (23.6%) | 6.181 (28.4%) | 3.724 (18.3%) |
| H02AB Glucocorticoids | 44 783 (5.1%) | 31.814 (4.0%) | 3.072 (8.3%) | 2.570 (8.7%) | 502 (6.7%) | 9.897 (23.5%) | 6.177 (28.4%) | 3.720 (18.3%) |
| J01 Antibacterials for systemic use | 156 686(17.8%) | 128.371(16.0%) | 10.337 (27.8%) | 8.492 (28.6%) | 1.845 (24.6%) | 17.978 (42.8%) | 11.347 (52.2%) | 6.631 (32.7%) |
| J01C Beta-lactam antibacterials, penicillins | 66 454 (7.5%) | 55.560 (6.9%) | 3.936 (10.6%) | 3.229 (10.9%) | 707 (9.4%) | 6.958 (16.5%) | 4.760 (21.9%) | 2.198 (10.8%) |
| J01D Other beta-lactam antibacterials | 34 531 (3.9%) | 23.189 (2.9%) | 2.760 (7.4%) | 2.397 (8.1%) | 363 (4.8%) | 8.582 (20.4%) | 5.755 (26.5%) | 2.827 (13.9%) |
| J01E Sulfonamides and trimethoprim | 3 580 (0.4%) | 2.378 (0.3%) | 366 (1.0%) | 334 (1.1%) | 32 (0.4%) | 836 (2.0%) | 689 (3.2%) | 147 (0.7%) |
| J01F Macrolides, lincosamides and streptogramins | 43 404 (4.9%) | 34.516 (4.3%) | 2.786 (7.5%) | 2.179 (7.3%) | 607 (8.1%) | 6.102 (14.5%) | 3.408 (15.7%) | 2.694 (13.3%) |
| J01G Aminoglycoside antibacterials | 878 (0.1%) | 538 (0.1%) | 74 (0.2%) | 66 (0.2%) | 8 (0.1%) | 266 (0.6%) | 232 (1.1%) | 34 (0.2%) |
| J01M Quinolone antibacterials | 24 953 (2.8%) | 17.661 (2.2%) | 2.329 (6.3%) | 2.088 (7.0%) | 241 (3.2%) | 4.963 (11.8%) | 3.606 (16.6%) | 1.357 (6.7%) |
| J01R Combinations of antibacterials | 623 (0.1%) | 568 (0.1%) | 27 (0.1%) | 22 (0.1%) | 5 (0.1%) | 28 (0.1%) | 16 (0.1%) | 12 (0.1%) |
| J01X Other antibacterials | 34 403 (3.9%) | 28.244 (3.5%) | 2.572 (6.9%) | 2.116 (7.1%) | 456 (6.1%) | 3.587 (8.5%) | 2.629 (12.1%) | 958 (4.7%) |
| J05 Antivirals for systemic use | 8 847 (1.0%) | 6.287 (0.8%) | 499 (1.3%) | 413 (1.4%) | 86 (1.1%) | 2.061 (4.9%) | 1.063 (4.9%) | 998 (4.9%) |
| J05A Direct-acting antiviral drugs | 8 847 (1.0%) | 6.287 (0.8%) | 499 (1.3%) | 413 (1.4%) | 86 (1.1%) | 2.061 (4.9%) | 1.063 (4.9%) | 998 (4.9%) |
| L Antineoplastic and immunomodulatory agents | 23 305 (2.6%) | 17.459 (2.2%) | 1.840 (4.9%) | 1.607 (5.4%) | 233 (3.1%) | 4.006 (9.5%) | 2.513 (11.6%) | 1.493 (7.4%) |

| | | | | | | | | |
|---|----------------|-----------------|----------------|----------------|---------------|----------------|----------------|---------------|
| L01 Antineoplastic agents | 4 136 (0.5%) | 2.683 (0.3%) | 434 (1.2%) | 400 (1.3%) | 34 (0.5%) | 1.019 (2.4%) | 786 (3.6%) | 233 (1.1%) |
| L01X Other antineoplastic agents | 2 451 (0.3%) | 1.519 (0.2%) | 302 (0.8%) | 283 (1.0%) | 19 (0.3%) | 630 (1.5%) | 501 (2.3%) | 129 (0.6%) |
| L01XX05 Hydroxycarbamide/Hydroxyurea | 443 (0.1%) | 235 (0.0%) | 127 (0.3%) | 125 (0.4%) | 2 (0.0%) | 81 (0.2%) | 78 (0.4%) | 3 (0.0%) |
| L02 Endocrine therapy | 5 834 (0.7%) | 4.403 (0.5%) | 556 (1.5%) | 500 (1.7%) | 56 (0.7%) | 875 (2.1%) | 653 (3.0%) | 222 (1.1%) |
| L02A Hormones and related agents | 2720 (0.3%) | 1.808 (0.2%) | 337 (0.9%) | 312 (1.1%) | 25 (0.3%) | 575 (1.4%) | 449 (2.1%) | 126 (0.6%) |
| L02B Hormone antagonists and related agents | 3 803 (0.4%) | 3.082 (0.4%) | 292 (0.8%) | 252 (0.8%) | 40 (0.5%) | 429 (1.0%) | 299 (1.4%) | 130 (0.6%) |
| L03A Immunostimulants | 1 639 (0.2%) | 1.077 (0.1%) | 84 (0.2%) | 74 (0.2%) | 10 (0.1%) | 478 (1.1%) | 323 (1.5%) | 155 (0.8%) |
| L04A Immunosuppressants | 13 155 (1.5%) | 10.186 (1.3%) | 867 (2.3%) | 721 (2.4%) | 146 (1.9%) | 2.102 (5.0%) | 1.105 (5.1%) | 997 (4.9%) |
| M01 Anti-inflammatory and antirheumatic products | 170 874(19.4%) | 155.790 (19.4%) | 6.652 (17.9%) | 5.168 (17.4%) | 1.484 (19.8%) | 8.432 (20.1%) | 4.111 (18.9%) | 4.321 (21.3%) |
| M01A Anti-inflammatory and antirheumatic products, non-steroids | 169 812(19.2%) | 154.874 (19.3%) | 6.578 (17.7%) | 5.101 (17.2%) | 1.477 (19.7%) | 8.360 (19.9%) | 4.067 (18.7%) | 4.293 (21.1%) |
| N03A Antiepileptics | 39 658 (4.5%) | 31.077 (3.9%) | 3.679 (9.9%) | 3.371 (11.4%) | 308 (4.1%) | 4.902 (11.7%) | 3.493 (16.1%) | 1.409 (6.9%) |
| N05 Psycholeptics | 158 162(17.9%) | 127.359 (15.9%) | 13.500 (36.3%) | 12.083 (40.7%) | 1.417 (18.9%) | 17.303 (41.1%) | 11.575 (53.2%) | 5.728 (28.2%) |
| N05A Antipsychotics | 38 386 (4.3%) | 28.667 (3.6%) | 3.754 (10.1%) | 3.352 (11.3%) | 402 (5.4%) | 5.965 (14.2%) | 4.324 (19.9%) | 1.641 (8.1%) |
| N05B Anxiolytics | 118 541(13.4%) | 96.771 (12.0%) | 9.539 (25.7%) | 8.522 (28.7%) | 1.017 (13.6%) | 12.231 (29.1%) | 8.098 (37.2%) | 4.133 (20.4%) |
| N05C Hypnotics and sedatives | 32 824 (3.7%) | 25.035 (3.1%) | 3.220 (8.7%) | 2.940 (9.9%) | 280 (3.7%) | 4.569 (10.9%) | 3.250 (14.9%) | 1.319 (6.5%) |
| N06 Psychoanaleptics | 89 785 (10.2%) | 72.612 (9.0%) | 8.011 (21.5%) | 7.240 (24.4%) | 771 (10.3%) | 9.162 (21.8%) | 6.456 (29.7%) | 2.706 (13.3%) |
| N06A Antidepressants | 89 785 (10.2%) | 72.612 (9.0%) | 8.011 (21.5%) | 7.240 (24.4%) | 771 (10.3%) | 9.162 (21.8%) | 6.456 (29.7%) | 2.706 (13.3%) |
| R03 Drugs for obstructive airway diseases | 67 622 (7.7%) | 52.928 (6.6%) | 5.184 (13.9%) | 4.525 (15.2%) | 659 (8.8%) | 9.510 (22.6%) | 6.288 (28.9%) | 3.222 (15.9%) |
| R03A Adrenergic, inhalants | 51 322 (5.8%) | 40.259 (5.0%) | 3.766 (10.1%) | 3.242 (10.9%) | 524 (7.0%) | 7.297 (17.4%) | 4.828 (22.2%) | 2.469 (12.2%) |
| R03B Other drugs for obstructive airway diseases, inhalants | 19 887 (2.3%) | 12.819 (1.6%) | 1.920 (5.2%) | 1.740 (5.9%) | 180 (2.4%) | 5.148 (12.2%) | 3.699 (17.0%) | 1.449 (7.1%) |
| R03D Other systemic drugs for obstructive airway diseases | 16 508 (1.9%) | 13.396 (1.7%) | 1.187 (3.2%) | 1.065 (3.6%) | 122 (1.6%) | 1.925 (4.6%) | 1.268 (5.8%) | 657 (3.2%) |

Table S4. Baseline characteristics by gender

| COVID-19 ANTITHROMBOTIC USERS n=79,234 (9%) | | | | | | | | | | | | | | | | | | |
|--|-------------------------------|--------------------------------|---------------------------------------|--------------------------------|--|-------------------------------|---|-------------------------------|--|-----------------------------|---------------------------------------|-------------------------------|---|------------------------------|---|-----------------------------|--|------------------------------|
| CHARACTERISTICS | ALL CASES n=882,540 (100%) | | COVID-19 NON-USERS n=803,306 (91%) | | PRIMARY CARE - GLOBAL n=37,183 (46,9%) | | PRIMARY CARE – PRIOR USERS n=29,678 (79,8%) | | PRIMARY CARE – NEW USERS n=7,505 (20,2%) | | HOSPITAL - GLOBAL n=42,051 (53,1%) | | HOSPITAL – PRIOR USERS n=21,751 (51,7%) | | HOSPITAL – NEW USERS n=20,300 (48,3%) | | POSTDISCHARGE USERS n=6,686 (0,2%) | |
| | MALE n=411,273 (46,6%) | FEMALE n=471,267 (53,4%) | MALE n=370,296 (46,1%) | FEMALE n=433,010 (53,9%) | MALE n=17,639 (47,4%) | FEMALE n=19,544 (52,6%) | MALE n=15,215 (51,3%) | FEMALE n=14,463 (48,7%) | MALE n=2424 (32,3%) | FEMALE n=5081 (67,7%) | MALE n=23,338 (55,5%) | FEMALE n=18,713 (45,5%) | MALE n=11,887 (54,7%) | FEMALE n=9,864 (45,3%) | MALE 8,849 (45,6%) | FEMALE 11,451 (56,4%) | MALE n=3,027 (45,3%) | FEMALE n=3,659 (54,7%) |
| | | | | | | | | | | | | | | | | | | |
| Age (y) | | | | | | | | | | | | | | | | | | |
| Mean/median | 46.9 / 45 years | 47.9 / 46 years | 44.6 / 43 years | 46.0 / 44 years | 67.6 / 68.0 years | 67.8 / 73 years | 69.5 / 70.0 years | 74.5 / 78 years | 55.6 / 55.0 years | 48.4 / 43 years | 66.9 / 68.0 years | 69.4 / 73 years | 74.3 / 76.0 years | 77.1 / 81 years | 59.3 / 59.0 years | 60.8 / 61 years | 70.9 / 73.0 years | 74.8 / 79 years |
| 18-25 | 49155 (12%) | 51449 (10.9%) | 48890 (13.2%) | 50884 (11.8%) | 474 (0.6%) | 2586 (1.6%) | 172 (0.2%) | 320 (0.3%) | 302 (3%) | 1980 (5.4%) | 1231 (0.7%) | 1349 (1.3%) | 154 (0.1%) | 249 (0.3%) | 1100 (2.5%) | 1077 (1.3%) | 107 (0.6%) | 17 (0.2%) |
| 25-40 | 103653 (25.2%) | 119716 (25.4%) | 101948 (27.5%) | 115781 (26.7%) | 474 (2.7%) | 2586 (13.2%) | 172 (1.1%) | 320 (4%) | 302 (12.4%) | 1980 (39%) | 1231 (5.3%) | 1349 (7.2%) | 154 (1.3%) | 249 (2.5%) | 1100 (12.4%) | 1077 (9.4%) | 107 (3.5%) | 17 (2.6%) |
| 40-55 | 127619 (31%) | 148368 (31.5%) | 121001 (32.7%) | 143512 (33.1%) | 2518 (14.3%) | 2240 (11.5%) | 1718 (11.3%) | 1152 (7.6%) | 800 (33%) | 1088 (21.4%) | 4100 (17.6%) | 2616 (14%) | 861 (7.2%) | 642 (6.5%) | 1974 (22.3%) | 3239 (28.3%) | 246 (8.1%) | 392 (10.7%) |
| 55-70 | 80026 (19.5%) | 83483 (17.7%) | 66776 (18%) | 75731 (17.5%) | 6458 (36.6%) | 3670 (18.8%) | 5665 (37.2%) | 2797 (18.4%) | 793 (33%) | 873 (17.2%) | 6792 (29.1%) | 4082 (21.8%) | 2857 (24%) | 1560 (15.8%) | 2522 (28.5%) | 3935 (34.4%) | 526 (17.4%) | 1044 (28.5%) |
| >70 | 50820 (12.4%) | 68251 (14.5%) | 31681 (8.6%) | 47102 (10.9%) | 8091 (45.9%) | 10728 (54.9%) | 7628 (50.1%) | 9862 (64.8%) | 463 (19.1%) | 866 (17%) | 11048 (47.3%) | 10421 (55.7%) | 8000 (67.3%) | 7385 (74.9%) | 3036 (34.3%) | 3048 (26.6%) | 2131 (70.4%) | 2122 (58%) |
| Comorbidities | | | | | | | | | | | | | | | | | | |
| Obesity | 40.076 (9.7%) | 56.924 (12.1%) | 32.110 (8.7%) | 48.219 (11.1%) | 3.660 (20,7%) | 4.083 (23,1%) | 3293 (21,6%) | 3483 (24,1%) | 367 (15,1%) | 600 (11,8%) | 4309 (18,5%) | 4619 (24,7%) | 4309 (36,2%) | 2758 (28,5%) | 1713 (19,4%) | 1861 (21%) | 829 (27,4%) | 835 (22,8%) |
| Cardiovascular diseases | 117.895 (28.7%) | 120.281 (25.5%) | 89.889 (24.3%) | 96.060 (22.2%) | 13.883 (78,7%) | 12.608 (71,5%) | 13034 (85,7%) | 11396 (78,8%) | 849 (35%) | 1212 (23,9%) | 14123 (60,5%) | 11613 (62,1%) | 9527 (80,1%) | 7806 (80,6%) | 4596 (51,9%) | 3807 (43%) | 2710 (89,5%) | 2218 (60,6%) |
| Hypertension | 93.482 (22.7%) | 97.872 (20.8%) | 71.225 (19.2%) | 76.819 (17.7%) | 10.471 (59,4%) | 10.698 (60,6%) | 9743 (64%) | 9668 (66,8%) | 728 (30%) | 1030 (20,3%) | 11786 (50,5%) | 10355 (55,3%) | 1178 (9,9%) | 6936 (71,6%) | 4132 (46,7%) | 3419 (38,6%) | 2184 (72,2%) | 1970 (53,8%) |
| Heart insufficiency | 7.601 (1.8%) | 9.237 (2%) | 4.160 (1.1%) | 5.387 (1.2%) | 1.337 (7,6%) | 1.827 (10,4%) | 1304 (8,6%) | 1778 (12,3%) | 33 (1,4%) | 49 (1%) | 2104 (9%) | 2023 (10,8%) | 2104 (17,7%) | 1807 (18,7%) | 186 (2,1%) | 216 (2,4%) | 439 (14,5%) | 442 (12,1%) |
| Arrythmia | 29.665 (7.2%) | 31.952 (6.8%) | 21.361 (5.8%) | 24.367 (5.6%) | 4.330 (24,5%) | 4.428 (25,1%) | 4189 (27,5%) | 4204 (29,1%) | 141 (5,8%) | 224 (4,4%) | 3974 (17%) | 3157 (16,9%) | 3974 (33,4%) | 2628 (27,1%) | 608 (6,9%) | 529 (6%) | 868 (28,7%) | 676 (18,5%) |
| Ischemic heart disease | 18.936 (4.6%) | 10.765 (2.3%) | 10.446 (2.8%) | 6.905 (1.6%) | 5.312 (30,1%) | 2.361 (13,4%) | 5282 (34,7%) | 2323 (16,1%) | 30 (1,2%) | 38 (0,7%) | 3178 (13,6%) | 1499 (8%) | 3178 (26,7%) | 1349 (13,9%) | 188 (2,1%) | 150 (1,7%) | 853 (28,2%) | 383 (10,5%) |
| Coronary artery disease | 12.435 (3%) | 6.554 (1.4%) | 6.326 (1.7%) | 3.685 (0.9%) | 3.794 (21,5%) | 1.782 (10,1%) | 3775 (24,8%) | 1759 (12,2%) | 19 (0,8%) | 23 (0,5%) | 2315 (9,9%) | 1087 (5,8%) | 2315 (19,5%) | 1025 (10,6%) | 80 (0,9%) | 62 (0,7%) | 699 (23,1%) | 318 (8,7%) |
| Myocardial infarction | 7.934 (1.9%) | 2.529 (0.5%) | 3.805 (1%) | 1.303 (0.3%) | 2.749 (15,6%) | 827 (4,7%) | 2739 (18%) | 819 (5,7%) | 10 (0,4%) | 8 (0,2%) | 1380 (5,9%) | 399 (2,1%) | 1380 (11,6%) | 376 (3,9%) | 37 (0,4%) | 23 (0,3%) | 362 (12%) | 103 (2,8%) |

| | | | | | | | | | | | | | | | | | | |
|---------------------|--------|--------|--------|--------|---------|---------|---------|---------|--------|--------|---------|---------|---------|---------|---------|--------|---------|---------|
| | 3.053 | 3.815 | 1.804 | 2.540 | 633 | 707 | 619 | 670 | 14 | 37 | 616 | 568 | 616 | 473 | 63 | 95 | 130 | 117 |
| Valvopathies | (0.7%) | (0.8%) | (0.5%) | (0.6%) | (3,6%) | (4%) | (4,1%) | (4,6%) | (0,6%) | (0,7%) | (2,6%) | (3%) | (5,2%) | (4,9%) | (0,7%) | (1,1%) | (4,3%) | (3,2%) |
| Peripheral artery | 4.821 | 2.077 | 2.491 | 1.399 | 1.239 | 399 | 1227 | 387 | 12 | 12 | 1091 | 279 | 1091 | 239 | 78 | 40 | 250 | 58 |
| disease | (1.2%) | (0.4%) | (0.7%) | (0.3%) | (7%) | (2,3%) | (8,1%) | (2,7%) | (0,5%) | (0,2%) | (4,7%) | (1,5%) | (9,2%) | (2,5%) | (0,9%) | (0,5%) | (8,3%) | (1,6%) |
| | 23.997 | 30.849 | 18.091 | 26.006 | 2.401 | 2.191 | 2248 | 1930 | 153 | 261 | 3505 | 2652 | 3505 | 1802 | 993 | 850 | 576 | 417 |
| Cancer history | (5.8%) | (6.5%) | (4.9%) | (6%) | (13,6%) | (12,4%) | (14,8%) | (13,3%) | (6,3%) | (5,1%) | (15%) | (14,2%) | (29,5%) | (18,6%) | (11,2%) | (9,6%) | (19%) | (11,4%) |
| Hereditary | 186 | 468 | 131 | 372 | 39 | 72 | 34 | 54 | 5 | 18 | 16 | 24 | 16 | 19 | 1 | 5 | 5 | 8 |
| thrombophilia | (0%) | (0.1%) | (0%) | (0.1%) | (0,2%) | (0,4%) | (0,2%) | (0,4%) | (0,2%) | (0,4%) | (0,1%) | (0,1%) | (0,1%) | (0,2%) | (0%) | (0,1%) | (0,2%) | (0,2%) |
| | 10.056 | 10.326 | 5.203 | 5.759 | 2.713 | 2.902 | 2696 | 2859 | 17 | 43 | 2140 | 1665 | 2140 | 1564 | 127 | 101 | 511 | 416 |
| Stroke | (2.4%) | (2.2%) | (1.4%) | (1.3%) | (15,4%) | (16,5%) | (17,7%) | (19,8%) | (0,7%) | (0,8%) | (9,2%) | (8,9%) | (18%) | (16,2%) | (1,4%) | (1,1%) | (16,9%) | (11,4%) |
| | 9.381 | 9.586 | 4.734 | 5.159 | 2.644 | 2.827 | 2630 | 2790 | 14 | 37 | 2039 | 1564 | 2039 | 1490 | 96 | 74 | 499 | 401 |
| Ischemic stroke | (2.3%) | (2%) | (1.3%) | (1.2%) | (15%) | (16%) | (17,3%) | (19,3%) | (0,6%) | (0,7%) | (8,7%) | (8,4%) | (17,2%) | (15,4%) | (1,1%) | (0,8%) | (16,5%) | (11%) |
| | 1.025 | 1.070 | 708 | 775 | 137 | 150 | 134 | 143 | 3 | 7 | 180 | 145 | 180 | 114 | 38 | 31 | 32 | 26 |
| Hemorrhagic stroke | (0.2%) | (0.2%) | (0.2%) | (0.2%) | (0,8%) | (0,9%) | (0,9%) | (1%) | (0,1%) | (0,1%) | (0,8%) | (0,8%) | (1,5%) | (1,2%) | (0,4%) | (0,4%) | (1,1%) | (0,7%) |
| | 60 | 43 | 52 | 33 | 3 | 6 | 2 | 6 | 1 | 0 | 5 | 4 | 5 | 2 | 2 | 2 | 0 | 0 |
| Acute liver disease | (0%) | (0%) | (0%) | (0%) | (0%) | (0%) | (0%) | (0%) | (0%) | (0%) | (0%) | (0%) | (0%) | (0%) | (0%) | (0%) | (0%) | (0%) |
| | 8.894 | 9.423 | 5.467 | 6.166 | 1.359 | 1.532 | 1310 | 1470 | 49 | 62 | 2068 | 1725 | 2068 | 1409 | 360 | 316 | 394 | 368 |
| CKD | (2.2%) | (2%) | (1.5%) | (1.4%) | (7,7%) | (8,7%) | (8,6%) | (10,2%) | (2%) | (1,2%) | (8,9%) | (9,2%) | (17,4%) | (14,5%) | (4,1%) | (3,6%) | (13%) | (10,1%) |
| | 12.500 | 5.462 | 8.026 | 4.138 | 1.634 | 575 | 1543 | 521 | 91 | 54 | 2840 | 749 | 2840 | 554 | 707 | 195 | 530 | 146 |
| COPD | (3%) | (1.2%) | (2.2%) | (1%) | (9,3%) | (3,3%) | (10,1%) | (3,6%) | (3,8%) | (1,1%) | (12,2%) | (4%) | (23,9%) | (5,7%) | (8%) | (2,2%) | (17,5%) | (4%) |
| | 33.175 | 44.799 | 30.711 | 40.596 | 1.005 | 2.024 | 825 | 1515 | 180 | 509 | 1459 | 2179 | 1459 | 1301 | 748 | 878 | 221 | 374 |
| Asthma | (8.1%) | (9.5%) | (8.3%) | (9.4%) | (5,7%) | (11,5%) | (5,4%) | (10,5%) | (7,4%) | (10%) | (6,3%) | (11,6%) | (12,3%) | (13,4%) | (8,5%) | (9,9%) | (7,3%) | (10,2%) |
| | 536 | 1.208 | 467 | 1.098 | 30 | 40 | 25 | 26 | 5 | 14 | 39 | 70 | 39 | 31 | 16 | 39 | 5 | 8 |
| Multiple sclerosis | (0.1%) | (0.3%) | (0.1%) | (0.3%) | (0,2%) | (0,2%) | (0,2%) | (0,2%) | (0,2%) | (0,3%) | (0,2%) | (0,4%) | (0,3%) | (0,3%) | (0,2%) | (0,4%) | (0,2%) | (0,2%) |
| | 1.926 | 2.199 | 1.157 | 1.448 | 304 | 354 | 287 | 321 | 17 | 33 | 465 | 397 | 465 | 291 | 102 | 106 | 77 | 76 |
| Parkinson's disease | (0.5%) | (0.5%) | (0.3%) | (0.3%) | (1,7%) | (2%) | (1,9%) | (2,2%) | (0,7%) | (0,6%) | (2%) | (2,1%) | (3,9%) | (3%) | (1,2%) | (1,2%) | (2,5%) | (2,1%) |
| | 2.812 | 7.786 | 1.649 | 5.157 | 434 | 1.436 | 404 | 1314 | 30 | 122 | 729 | 1193 | 729 | 918 | 145 | 275 | 105 | 225 |
| Dementia | (0.7%) | (1.7%) | (0.4%) | (1.2%) | (2,5%) | (8,1%) | (2,7%) | (9,1%) | (1,2%) | (2,4%) | (3,1%) | (6,4%) | (6,1%) | (9,5%) | (1,6%) | (3,1%) | (3,5%) | (6,1%) |
| | 2.625 | 4.169 | 776 | 2.828 | 185 | 716 | 172 | 634 | 13 | 82 | 323 | 625 | 323 | 464 | 75 | 161 | 43 | 116 |
| Alzheimer | (0.6%) | (0.9%) | (0.2%) | (0.7%) | (1%) | (4,1%) | (1,1%) | (4,4%) | (0,5%) | (1,6%) | (1,4%) | (3,3%) | (2,7%) | (4,8%) | (0,8%) | (1,8%) | (1,4%) | (3,2%) |
| | 2.824 | 2.940 | 2.504 | 2.692 | 132 | 122 | 113 | 86 | 19 | 36 | 188 | 126 | 188 | 73 | 89 | 53 | 28 | 13 |
| IBD | (0.7%) | (0.6%) | (0.7%) | (0.6%) | (0,7%) | (0,7%) | (0,7%) | (0,6%) | (0,8%) | (0,7%) | (0,8%) | (0,7%) | (1,6%) | (0,8%) | (1%) | (0,6%) | (0,9%) | (0,4%) |